Basilea Pharmaceutica AG (BPMUF)
| Market Cap | 1.09B +59.1% |
| Revenue (ttm) | 306.21M +4.7% |
| Net Income | 64.83M -27.9% |
| EPS | 4.90 -26.7% |
| Shares Out | n/a |
| PE Ratio | 15.79 |
| Forward PE | 12.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 76.25 |
| Previous Close | 76.25 |
| Day's Range | 76.25 - 77.40 |
| 52-Week Range | 59.29 - 77.40 |
| Beta | 0.32 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 18, 2026 |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a cli... [Read more]
Financial Performance
In 2025, Basilea Pharmaceutica AG's revenue was 232.38 million, an increase of 11.43% compared to the previous year's 208.54 million. Earnings were 40.24 million, a decrease of -48.14%.
Financial numbers in CHF Financial StatementsNews
Basilea Pharmaceutica AG Press release: FY 2026
Basilea Pharmaceutica AG issued a press release on October 28, 2026, disclosing material business information to investors.
Basilea Pharmaceutica AG Slides: Investor presentation
Basilea Pharmaceutica AG has posted slides in relation to its latest quarterly earnings report, which was published on October 27, 2026.
Basilea price target raised to CHF 110 from CHF 105 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Basilea Pharmaceutica (BPMUF) to CHF 110 from CHF 105 and keeps a Buy rating on the shares. The company’s key pivotal program…
Basilea Pharmaceutica AG Earnings Call Transcript: H1 2026
Revenue grew 14% year-on-year to CHF 119 million, with operating profit up 32% and net profit at CHF 27.9 million. Strong Cresemba sales and Zevtera's U.S. launch drove growth, while guidance for 2026 was raised, reflecting higher expected revenue and profitability.
Basilea Pharmaceutica AG Quarterly report: H1 2026
Basilea Pharmaceutica AG has published its H1 2026 quarterly earnings report on August 18, 2026.
Basilea Pharmaceutica AG Slides: H1 2026
Basilea Pharmaceutica AG has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 18, 2026.
Basilea Pharmaceutica AG Earnings release: H1 2026
Basilea Pharmaceutica AG released its H1 2026 earnings on August 18, 2026, summarizing the period's financial results.
Basilea Pharmaceutica AG Slides: Investor presentation
Basilea Pharmaceutica AG has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Basilea Pharmaceutica AG Slides: Investor presentation
Basilea Pharmaceutica AG has posted slides in relation to its latest quarterly earnings report, which was published on June 30, 2026.
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the ...
Basilea Pharmaceutica AG Slides: Investor presentation
Basilea Pharmaceutica AG has posted slides in relation to its latest quarterly earnings report, which was published on May 28, 2026.
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Allschwil, Switzerland, April 15, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in...
Basilea Pharmaceutica AG Slides: Investor presentation
Basilea Pharmaceutica AG has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
Basilea Pharmaceutica AG Slides: Investor presentation
Basilea Pharmaceutica AG has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Allschwil, Switzerland, March 23, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 25, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
Basilea Pharmaceutica AG Slides: Investor presentation
Basilea Pharmaceutica AG has posted slides in relation to its latest quarterly earnings report, which was published on February 25, 2026.
Basilea Pharmaceutica AG Earnings Call Transcript: H2 2025
2025 saw robust revenue and profit growth, driven by Cresemba's global momentum and Zevtera's U.S. launch. The pipeline expanded with new phase 3 assets, and significant non-dilutive funding was secured, positioning for sustained growth despite upcoming generic competition for Cresemba.
Basilea Pharmaceutica AG Annual report: H2 2025
Basilea Pharmaceutica AG has published its H2 2025 annual report on February 17, 2026.
Basilea Pharmaceutica AG Earnings release: H2 2025
Basilea Pharmaceutica AG released its H2 2025 earnings on February 17, 2026, summarizing the period's financial results.
Basilea Pharmaceutica AG Slides: H2 2025
Basilea Pharmaceutica AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 17, 2026.
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
15% royalty income increase 11% total revenue increase Tripled net cash position Phase 3 program with fosmanogepix progressing as planned Financial guidance FY 2026: Double-digit increase in total rev...
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, February 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteria...
Basilea provides portfolio update and outlook
Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infect...